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Abstract 
Radiomics is a nascent field in quantitative imaging that uses advanced algorithms and considerable 
computing power to describe tumor phenotypes, monitor treatment response, and assess normal tissue 
toxicity quantifiably. Remarkable interest has been drawn to the field due to its noninvasive nature and 
potential for diagnosing and predicting patient prognosis. This review will attempt to comprehensively 
and critically discuss the various aspects of radiomics including its workflow, applications to different 
modalities, potential applications in cancer radiotherapy, and limitations. 
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1. Introduction 
Cancer can be diagnosed and monitored through many different measures such as lab tests, biopsies, 
and imaging procedures. Minimally invasive lab tests specifically tailored for each cancer can monitor 
cancer biomarkers such as prostate-specific antigens (PSAs) (1), alpha-fetoprotein (AFP), or 
carcinoembryonic antigen (CEA) in the blood that might signify cancer progression or treatment 
response. The dilemma of observing biomarker levels only through laboratory testing is that it is just one 
measure of specific cancer cells that should be supplemented by other sources of information such as 
biopsies and medical images. 
The standard method to identify and characterize tumors based on genetic and pathologic 
factors is through tissue biopsies. Biopsies and associated genetic and histopathologic analyses are able 
to diagnose and provide more information about the cancer but also have limitations. Most tumors are 
spatially and temporally heterogeneous due to irregularities in metabolism, vasculature, oxygenation, 
and gene expression. Such heterogeneities can require multiple biopsies to acquire a complete 
assessment of the tumor, which increases the risk of complications for the patient. However, the use of 
advanced medical imaging to supplement traditional diagnostic methods has the potential to better 
assess spatial and temporal tumor dynamics.  
Medical imaging including computed tomography (CT), magnetic resonance imaging (MRI), 
positron emission tomography (PET), and ultrasound (US) can sample the entire tumor non-invasively 
multiple times while retaining the cellular and genetic information derived from phenotypic patterns. 
Although medical imaging is an ever advancing and powerful tool, many visible features derived from 
images are still being assessed qualitatively by humans. These assessments are often quite variable and 
subjective (2, 3). However, that is not to say that quantitative imaging (QI) methods such as dynamic 
susceptibility contrast enhanced (DSC) MRI (4) and MRI spectroscopy (5), that quantifies the amount of 
contrast or biochemical properties within the field of view (FOV) to evaluate blood perfusion and 
metabolism are not available. QI methods have the potential to provide a greater insight in the 
underlying tumor biology and could directly facilitate personalized treatments but are in the process of 
being integrated into clinical radiation oncology practice and will not be the focus of this review (6). 
Advancements in medical imaging is currently challenged by the limits of human observation and may 
be improved with the introduction of more objective and robust methods of extracting features from 
medical images. 
Radiomics involves the high-throughput extraction of advanced quantitative features invisible to 
the naked eye to objectively and quantitatively describe tumor phenotypes in medical imaging. These 
radiomics features are ‘mined’ from medical images using advanced algorithms that examine multiple 
dimensions of the image such as physical (shape and size), textural (the spatial arrangement of voxels) 
features, histogram-based, and filtered-based. The papers included in this review were derived from an 
initial search of the key word “radiomics” in PubMed in the last ten years. Once a considerable amount 
of papers were gathered, the relevant sources from these papers were also added to a manual review 
for a more complete view of the field of radiomics. Since other reviews of radiomics have shown the 
detailed workflow and much greater data extraction from medical images paving way for more 
personalized cancer therapy, this review will compliment others by providing a big picture look at each 
major imaging modality and cancer sites as well as discuss the future potential and limitations of 
radiomics. 
 
2. Workflow of Radiomics 
 Figure 1. The workflow of Radiomics. The key components of the radiomic workflow is shown: Image acquisition and 
segmentation, feature extraction and analysis, and model testing and validation. 
 
Current treatment decisions are based on a wide variety of traditional diagnostic tests. In recent years, 
radiomics has gained ground as a method in which one can  predict and associate clinical outcomes of 
many patients with cancers like glioblastoma multiforme (GBM) (7), breast cancer (8), renal cell cancer 
(9), and head and neck cancer (10). Any medical image can be used to derive radiological features and 
associate them with clinical value like disease diagnosis, progression, and overall survival. Simply put, 
radiomics is an advanced computational identification, diagnosis, and prediction of patient response 
through medical images. As such, it has three key components: 1) image, 2) analysis, and 3) validation. 
These components are fundamental to the workflow of radiomics (Figure 1) and are complex processes 
that involve many different parts. 
2.1 Imaging 
Non-invasive medical imaging, like CT, MRI, PET, US, allows healthcare professionals to interrogate the 
image volume for any irregularities like tumors. Each modality has its advantages such as PET’s ability to 
track glucose metabolism through radio-tracer uptake, MRI’s ability to discriminate various tissue and 
image tissue function through various pulse sequences, and CT’s asset in having electron density 
information for radiation therapy and dose calculations. To exploit these advantages and extract the 
most amount of relevant information, appropriate images are required for radiomic analysis. 
Broadly speaking, the imaging component of radiomics can be separated into two parts: 1) 
image acquisition and 2) image segmentation (11). Images are acquired through various physical 
processes, detection parameters, and reconstruction algorithms to create a two or three dimensional 
patient image. Then the image is segmented into the regions or volumes of interest to focus on the 
cancerous areas as well as cut down on computational workload. 
 
2.2 Analysis 
Once the image acquisition and segmentation is applied to an initial patient data set, also called the 
training set, it is then analyzed through different algorithms for features of statistical significance. The 
goal of radiomic analysis is to find unique radiomic features or groups of features, called a signature, for 
various sites, malignancies, and outcomes to allow a semi-automatic or automatic approach to more 
informed clinical decisions. These analytical methods often describe the image in a way humans can’t 
and allows algorithms to “mine” for data that may be correlated with clinical value. Methods can vary 
from histogram-based first order, co-occurrence-based second order, to matrix-based higher order 
texture analysis for MRI (12) and ultrasound (13). Texture analyses have been shown to predict 
chemotherapy response in non-small cell lung cancer (NSCLC) (14), differentiate prostate cancer by 
Gleason score (15), and show prognostic power in GBM (16). These features and signatures can be 
applied to even more detailed clinical applications such as tumor heterogeneity in glioblastomas (17) 
and tumor phenotype information (18, 19). 
 
2.3 Validation 
Once a feature or signature has been extracted from an image, it must be validated with another cohort, 
called a validation set, which is distinct from the original training set. The constant testing and retesting 
allows the researcher to strip away the redundant, poorly performing, or unstable features to get the 
best features that correlate with specific clinical parameters such as patient prognosis or tumor 
response to treatment as demonstrated in oropharyngeal, colorectal, and lung cancers (19-22).  
 
3. Review of Radiomics by Modality 
This paper summarizes various features into 4 categories as shown in Table 1: volume-based descriptors 
(C1), statistics based descriptors (C2), model based descriptors (C3), and other descriptors (C4). Volume 
based descriptors are features regarding the physical tumor size, shape, location, etc. Statistics based 
descriptors are varying orders of statistical outputs that describe the image such as 1st order (C2a) 
statistics (comparing the pixel individually) like mean, standard deviation, kurtosis, skewness, etc.; 2nd 
order (C2b) statistics (comparing pairs of pixels) like contrast, entropy, inertia, homogeneity, etc.; and 
higher order (C2c) statistics (comparing multiple pixels) like grey-level run length matrices. Model based 
descriptors are features derived from models, like fractal models, that describe an image (23) consistent 
with tumor progression. Finally, other method based descriptors are features derived from some 
processing of the raw or reconstructed imaging data like Nagakami parameters in ultrasound (24, 25) or 
Gabor filters (26). 
  
Table 1. Radiomics feature categories 
Category Name Descriptors and examples 
C1 Volume-based Tumor size, shape, location, etc. 
C2 Statistics-based  
C2a 1st order statistics 
Mean, median, standard deviation,  
kurtosis, skewness, quartiles, min/max, etc. 
C2b 2nd order statistics 
Contrast, energy, entropy, correlation,  
inertia, cluster prominence, cluster shade,  
homogeneity, dissimilarity, etc. 
C2c Higher order statistics 
Grey-level run length matrices,  
grey-level size zone matrices,  
neighborhood gray-tone difference  
matrices, etc. 
C3 Model-based Fractal analysis 
C4 Other methods 
Wavelets, Gabor transform,  
Nakagami parameters, contourlet, etc. 
C5 Signatures 
Four or more features used  
together or separately 
 
Radiomics has become a hot topic in recent years. As seen in Fig. 1, over 78% of the papers with 
the radiomic features outlined in Table 1, were published in the last 5 years, from 2012 to 2016. This 
may be a response to the increased interest in personalized medicine, enhanced computing power, and 
large databases to extract information from. A list of papers containing the features in Table 1 is sorted 
by modality in Table 2 and their distribution by modality is summarized in Figure 2a and 2b. When 
assessing these papers as a whole, the big three modalities of CT, MRI, and PET account for 74% of the 
papers published. Additionally, 56% are focused on three specific sites: brain, head and neck, and lung 
which are strongly associated with MRI, PET, and CT respectively. Overall, statistics based features 
usually referred to as texture features, C2a, C2b, and C2c, by far are the most common while the use of 
signatures have become more common with about 73% of papers using signatures being published in 
the last 2 years, 2015 and 2016. 
 Figure 2.  The number of radiomic study publications by year of publication. 
 
 
Table 2. List of Radiomic Feature Categories by Modality. 
Modality Author   Year General Site 
Specific 
Cancer/Disea
se 
Feature Category 
4DCT Fave 2017 Lung NSCLC Signature 
CBCT Fave 2015 Lung NSCLC C2 
CE-CT Li 2014 Liver 
Hepatocellular 
carcinoma 
C1 and C4 
CE-CT Petkovska 2006 Lung  C2a 
CT Aerts 2014 
Head and Neck 
/Lung 
 Signature 
CT Aerts 2016 Lung NSCLC C2b 
CT 
Balagurunath
an 
2014 Lung NSCLC C1 
CT 
Balagurunath
an 
2014 Lung NSCLC C2c 
CT Coroller 2015 Lung NSCLC Signature 
CT Cunliffe 2015 Lung 
Radiation  
pneumonitis 
Signature 
CT Fave 2015 Lung NSCLC C2a and C2b 
CT Ganeshan 2010 Lung NSCLC C2 
CT Goh 2011 Kidneys Renal Cell C2 
CT Hayano 2016 Lung NSCLC C1 and C2b 
CT Huynh 2016 Lung NSCLC C1, C2c,and C4 
CT Huynh 2016 Lung NSCLC Signature 
CT Kido 2002 Lung  C3 
CT Kim 2005 Liver 
Hepatocellular 
carcinoma 
C2b 
CT Leijenaar 2015 Head and Neck Oropharyngeal  Signature 
CT Liang 2016 Colorectal  Signature 
CT McNitt-Gray 1999 Lung  C2b 
CT Parmar 2015 
Head and Neck 
/Lung 
 Signature 
CT Permuth 2016 Pancreas 
Pancreatic intraductal 
papillary mucinous 
neoplasms 
Signature 
CT Rao 2016 Colorectal 
Liver  
Metastasis 
C2 
CT Tateishi 2002 Lung  C2a 
CT Tian 2015 
Soft Tissue 
Sarcoma 
 C2 
CT Way 2006 Lung  Signature 
CT Yamamoto 2014 Lung NSCLC Signature 
CT Yip 2015 Head and Neck Esophageal C2a and C2b 
CT (DECT) Choi 2016 Lung NSCLC C1, C2a, and C2b 
CT/MRI Prasanna 2016 Multiple  C2c 
DCE-MRI Johansen 2009 Breast  C2a 
DCE-MRI Peng 2013 Brain  C2b 
DCE-MRI Shukla 2012 Head and Neck  C2b 
DW-MRI King 2013 Head and Neck 
Squamous cell 
carcinoma 
C2a 
Light 
microscopy 
Colen 2016 Brain CNS Signature 
MRI Baek 2012 Brain 
Glioblastoma 
multiforme 
C2a 
MRI Cameron 2016 Prostate  Signature 
MRI Coroller 2016 Brain Meningioma Signature 
MRI Diehn 2008 Brain 
Glioblastoma 
multiforme 
C1 
MRI Ellingson 2013 Brain 
Glioblastoma 
multiforme 
C1 
MRI Ginsburg 2016 Prostate  C2 and C4 
MRI Gnep 2017 Prostate  C2b 
MRI Gutman 2015 Brain 
Glioblastoma 
multiforme 
C1 
MRI Khalvati 2015 Prostate  Signature 
MRI Kickingereder 2016 Brain 
Glioblastoma 
multiforme 
Signature 
MRI Kjaer 1995 Brain  C2 
MRI Lerski 1993 Brain  C2 
MRI Li 2016 Breast  C1 and C2b 
MRI Lopez 2016 Brain Glioblastoma C1 
multiforme 
MRI 
Mahmoud-
Ghoneim 
2003 Brain  C2 
MRI Naeini 2013 Brain 
Glioblastoma 
multiforme 
C1 
MRI Nie 2008 Breast  C1, C2a, and C2b 
MRI Nie 2016 Rectum Rectal Cancer C2b 
MRI Obeid 2016 Breast 
Adipokines 
(fat specific cytokines) 
C2a 
MRI Prasanna 2016 Brain 
Glioblastoma 
multiforme 
C2b 
MRI 
Rios 
Velazquez 
2016 Breast  C1 and C2b 
MRI van den Burg 2016 Ear Meniere's Disease Signature 
MRI Wang 2015 Breast 
Parenchyma 
of the breast 
C2a 
MRI  Grossmann 2016 Brain 
Glioblastoma 
multiforme 
C2c 
MRI 
(Diffusion) 
Foroutan 2013 Bone  C2a 
PET Brooks 2014 Cervical  C1 
PET Cheng 2015 Head and Neck Oropharyngeal  C4 
PET Cook 2013 Lung NSCLC C2b 
PET Dong 2013 Head and Neck Esophageal C2a and C2b 
PET Doumou 2015 Head and Neck Esophageal C2b 
PET Eary 2008 Sarcoma  C2b 
PET Galavis 2010 Multiple 
Adrenal gland 
carcinoma, lung, 
epiglottis, and 
esophagus cancer 
C2b and C2c 
PET Grootjans 2016 Lung  C2c 
PET Haberkorn 1994 Animal Study* 
Spontaneous 
Mammary 
fibroadenoma, 
chemically-induced 
mammary 
adenocarcinoma and 
dunning prostate 
adenocarcinoma 
C2a 
PET Hatt 2013 Head and Neck Esophageal C2b and C2c 
PET Hatt 2015 Multiple  C1 and C2b 
PET Henriksson 2007 Animal Study* 
Head and neck 
squamous cell 
carcinoma 
C2a 
PET Higashi 1993 Adenocarcinoma  C2a 
PET Higgins 2012 Head and Neck  C2a 
PET Leijenaar 2013 Lung NSCLC Signature 
PET Mu 2015 Cervical  C2c 
PET Nair 2012 Lung NSCLC C2a 
PET Nyflot 2015 Phantom*  C2c 
PET Orlhac 2014 Multiple 
Metastatic colorectal 
cancer, non-small cell 
lung cancer, and 
breast cancer. 
C2a 
PET Rahmim 2016 Multi 
Oropharyngeal and 
pancreatic 
C2 
PET Rizk 2006 Head and Neck Esophageal C2a 
PET Tixier 2011 Head and Neck Esophageal C2b 
PET Tixier 2012 Head and Neck Esophageal C2b 
PET Tixier 2014 Lung NSCLC C2 
PET Yang  2015 Cervical  C2b and C2c 
PET Yip 2016 Head and Neck Esophageal C2b and C2c 
PET/CT Coroller 2016 Lung NSCLC Signature 
PET/CT 
Cortes-
Rodicio 
2016 Liver  C2c 
PET/CT Hatt 2011 Lung NSCLC C1 and C2b 
PET/MRI Antunes 2016 Kidneys Renal Cell C2a 
PET/MRI Vallieres 2015 Lung 
Soft tissue  
sarcomas 
Signature 
PET     /PET-
CT 
Didierlaurent 2012 *N/A  C2a 
PET     /PET-
CT 
Tan 2013 Head and Neck Esophageal C2a and C2b 
PET-CT Bundschuh 2014 Rectum Rectal Cancer C2 
PET-CT Cheng 2013 Head and Neck Oropharyngeal  C2b 
PET-CT Xu 2014 
Bone and soft 
tissue 
Malignant  
and benign 
C2b 
PET-CT Yang 2013 Cervical  C2 
PET-CT 
/4DPET 
Huang 2013 
Head and Neck 
/Lung 
 C2a 
PET-CT 
/DCE-CT 
Tixier 2014 Colorectal  C2b 
SPECT/CT Bowen 2016 Liver 
Hepatocellular 
carcinoma 
C1 
US Yang 2014 Head and Neck  C4 
US Yang 2015 Head and Neck  C4 
US Yang  2012 Head and Neck  C2a 
US Yang  2012 Head and Neck  C2b 
US Zhang 2015 Breast  C4 
US Zhang 2015 Breast  C4 
US Zhang 2017 Breast  C4 
*non-human studies 
 
 
3.1 Computed Tomography 
Computed tomography (CT) scan is the most common medical imaging modality in cancer therapy. It is 
used as a diagnostic tool for tumor assessment, treatment planning, dose calculations, as well as a 
quality assurance of patient position before treatment. The near-universal use of CT scans for patients 
undergoing cancer treatments is a tremendous asset for the field of radiomics. The wealth of CT data 
available for analysis as well as the ease of application makes radiomic analysis of CT images desirable. A 
review of the literature shows that out of all cancer sites, lung cancer utilizes CT imaging the most. 
 One of the earliest papers published for the use of radiomics in lung cancer was in 1999. McNitt-
Gray et. al. (27), showed that two different statistical features, correlation and difference entropy, were 
able to differentiate between benign and malignant solitary pulmonary nodules consistently. Other 
studies have supported the ability to use radiomic features to differentiate pulmonary nodules through 
different contrast enhancement features (28) and fractal analysis (29, 30). The Kido et. al paper 
suggested that through binary and gray scale fractal dimension calculations it may be possible to 
differentiate between benign and malignant pulmonary nodules as well as adenocarcinomas from 
squamous cell carcinomas. Fractal analysis has also been used in a hepatocellular carcinoma study 
where patients with favorable progression-free survival (PFS) showed lower fractal dimension on 
anterior-posterior (AP) contrast enhanced CT (CE-CT) images of patients treated with sunitinib, a 
receptor tyrosine kinase inhibitor commonly used for the treatment of renal cell carcinoma, 
gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors (30). Differentiation between 
other malignant and benign tumors such as intraductal papillary mucinous neoplasms (IPMN) is also 
possible through CT feature analysis (31). 
 The ability to distinguish benign and malignant tumors are important for pre-treatment 
assessments but for patients already undergoing therapy, identifying genomic phenotypes and their 
response to therapy is even more important for personalized and effective treatments. If the status of 
genomic mutations like vascular endothelial growth factor (VEGF), anaplastic lymphoma kinase (ALK), 
and epidermal growth factor receptor (EGFR) are known before or during treatment, the therapy can be 
intensified or deintensified to address those mutations specifically for better patient outcome and 
reduced morbidity. It has been demonstrated such identifications are viable and one study showed that 
high maximum attenuation values of dynamic CT scans are indicative of VEGF mutations and increased 
microvessel density before treatment (32). However, some mutations, ALK-rearranged (ALK+) and EGFR, 
are revealed by comparing pre and early/mid crizotiniband gefitinib, ALK and EGFR inhibitor respectively, 
treatment image features (33, 34). The changes in three features: central tumor location, absence of a 
pleural tail, and large a pleural effusion were strongly associated with ALK+ status and are highly 
discriminatory in patients under the age of 60 and those with operable disease i.e. stage IIIA or lower 
(33). Renal cell gene mutation analysis is in its preliminary stages but von Hippel-Lindau tumor 
suppressor (VHL), lysine (K)-specific demethylase 5C (KDM5C), BRCA1-associated protein 1 (BAP1), SET 
domain containing 2 (SETD2), and polybromo 1 (PBRM1) have all been associated with tumor features 
like tumor margins, nodular tumor enhancement, and gross appearance of intratumoral vascularity (35). 
 If mid-treatment adjustments are not viable or likely, accurate patient prognosis becomes even 
more important. Conventional features such as tumor volume and diameter have been used as 
prognostic indicators of overall survival (OS) for lung cancer but radiomic features offer more prognostic 
features in addition to OS. For example, run-length gray-level non-uniformity, Laplace of Gaussian (LoG) 
run low gray level short run emphasis, and stats median were all statistically significant features for 
patient survival, while features like wavelet LLH, a wavelet transform sequence involving low, low then 
high pass filters with down sampling applied to different dimensions of the data, stats range were 
associated with distant metastasis (DM), and other features were associated with locoregional 
recurrence (LRR) (20, 36-38). Similarly, in esophageal cancer, tumor texture became more homogeneous 
after neoadjuvant chemotherapy treatment with a significant decrease in entropy and increase in 
uniformity features (39). 
 
3.2 Positron Emission Tomography 
Positron emission tomography (PET) imaging is often used in cancer to survey the metabolic functions of 
tumors. The significant difference between PET and other imaging modalities is that the radiation 
originates from the patient through the absorption of radionuclides in the body. One of the most 
common radiotracer used in PET imaging is fludeoxyglucose (FDG) (40) as a glucose analog. Many 
cancers, due to their aggressive growth and irregular vasculature, have hypoxic areas that are associated 
with the reliance on glucose for energy (41). This relationship is further strengthened by the results of a 
study showing that FDG uptake value derived metagene features were the most prognostic in resected 
non-small cell lung cancer (42).  
 In retrospective studies of esophageal cancer patients, high mean standard uptake value 
(SUVmean) and maximum standard uptake value (SUVmax) were associated with poor disease-free survival 
(DFS) for patients treated with radiation therapy and lower three-year survival rate for patients that 
underwent surgical resection of the tumor respectively (43, 44). While SUV values have predictive 
powers on patient outcome, the correlation of standard TNM staging methods with SUVmax and tumor 
heterogeneity features, entropy and energy, show that radiomic features can compete with current 
prognostic models and predict non-response, partial-response, and complete-response to therapy with 
textural features having higher sensitivity than any SUV features (45, 46).  
Furthermore, it has been demonstrated with esophageal cancer patients undergoing 
chemotherapy that temporal changes in second and higher order statistical features had better 
correlation with pathological response and overall survival than SUV features (46). Similarly, lower 
coarseness, high contrast and busyness, total lesion glycolysis, and high-intensity emphasis showed 
better patient outcomes in NSCLC patients (14, 47). Additionally, a regional heterogeneity feature, zone-
size nonuniformity (ZSNU), was identified as an independent predictor of progression-free survival (PFS) 
and disease-specific survival (DSS) in oropharyngeal squamous cell carcinomas (48). Their risk 
stratification system performed better when ZSNU was combined with other prognostic parameters, 
total lesion glycolysis and uniformity, a local texture parameter. This suggests that textural features, 
second and higher order statistical features, describing tumor heterogeneity can provide more 
prognostic power than just first order SUV features. 
 
3.3 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) can be used for both functional imaging like PET as well as anatomic 
imaging like CT with the additional benefit of not using ionizing radiation. It has its disadvantages that 
will be discussed later but one of its advantages over CT is its ability to differentiate tissue types 
especially in cases of brain cancer where CT scans would have difficulty in identifying tumors within the 
brain. This advantage of MRIs allow for the use of conventional features like volume in the brain where 
MRI-derived volumetric features are significantly associated with and are predictive of several cancer-
relevant, drug-targetable DNA mutations in glioblastoma as well as the differentiation between 
mesenchymal (MES) glioblastoma (GBM) and non-MES GBM (49, 50). 
 This ability to discriminate between tissue and the use of radiomic features allow for advanced 
identification of tumors and their characteristics. Compared to conventional image analysis, 3D texture 
analysis approaches allow better discrimination between necrosis and edema versus solid tumor 
increasing the specificity and sensitivity of brain tumor characterization (51). Tumor differentiation 
through feature analysis has been observed as early as 1995 in mutual comparison of all tumor types 
with even specific tumor being successful in certain cases (52). In addition, multigene assay recurrence 
scores, pathologic response, and semantic features were all significantly associated with radiomic 
features in brain, breast, and prostate cancers with multi-parametric (MP) MRI feature models excelling 
in identifying tumors and predicting pathologic response than conventional models (53-57). Tumor 
contrast enhancement and mass effect also predicted the activation of specific hypoxia and proliferation 
gene expression programs respectively and showed that the phenotypic expression of these genes have 
multiple foci for GBMs and are related to significantly shorter survival (58). 
 Tumor heterogeneity, especially in MRIs continues to be an important factor in determining 
patient prognosis. Papers have discussed that various MRI derived features and values such as maximum 
full width at half maximum (mFWHM), entropy, metabolic tumor volumes (MTV), can allow for the 
identification of tumor heterogeneity in multiple breast and brain cancer types (59-61). The 
identification of heterogeneity features and others allow for prognostic evaluations to take place. For 
brain cancer, a subset of ten radiomic peritumoral brain zone (PBZ) MRI features and the histographic 
pattern of normalized cerebral blood volume were found to be predictive of survival as compared to 
other features such as enhancing tumours, necrotic regions, known clinical factors, and percent change 
of skewness or kurtosis (62, 63). For stage IV head-and-neck-squamous-cell-carcinoma (HNSCC) patients 
with nodal metastases K-trans, a measure of permeability or blood flow, was the strongest predictor of 
progression-free survival (PFS) and overall survival (OS) (64) while T2w MRI Haralick features were 
strongly associated with biochemical recurrence following prostate cancer radiotherapy (65). In T2-
weighted MRIs of prostate cancer, two textural features, contrast and homogeneity, were compared to 
the classic apparent diffusion coefficient (ADC) metric and were found to be better predictors of Gleason 
scores indicative of poorer patient prognosis (66). Additionally, it has been demonstrated in Viswanath 
et. al. (67) that central gland and peripheral zone prostate tumors have significantly different radiomic 
signatures alluding to the necessity of using tumor specific features for any classification or prediction 
problem. 
 While baseline or pre-treatment prognosis is important, identifying treatment response will 
quickly become the future of personalized medicine. It’s been shown that intratreatment features, like 
percent change in ADC, change in skewness or kurtosis, large area emphasis, and relative signal intensity 
AUC, have high potential to predict treatment response in patients with HNSCC, brain cancer, and breast 
cancer (68-70). 
 
3.4 Other modalities  
Radiomics is the extraction and association of image features with patient data. With multi-modality 
methods, the density of information that can be mined increases thus allowing a more thorough analysis 
of the data presented. PET/CT is one common method where blood flow visualization with DCE-CT was 
significantly associated with FDG-PET metabolically active volume and uptake heterogeneity for patients 
with stage 3/4 colorectal tumors (71). Similarly, four features extracted from CT and one from PET were 
significantly prognostic of distant metastases in NSCLC, the latter of which was also the most prognostic 
(72). This was supported by a study showing that texture features extracted from fused scans 
significantly outperformed those from separate scans in terms of lung metastases prediction estimates 
in PET/MRI images, the best performance being a combination of four texture features extracted from 
FDG-PET/T1 and FDG-PET/T2FS scans (11). Finally, one feature, co-occurrence of Local Anisotropic 
Gradient Orientations (CoLIAGe), could be applied to different situations and modalities: differentiation 
between radiation necrosis vs recurrent tumors in T1w MRI, different molecular sub-types of breast 
cancer in DCE-MRI, and NSCLC vs benign fungal infection on CT (73). 
 Another way to increase the information available for analysis is getting temporal information. 
The big hurdles for this are the increased radiation dose to patients with additional PET or CT images 
and cost for MRIs. A method to circumvent these obstacles is to use cone beam CT (CBCT). CBCT is a 
commonly imaging modality used before each fraction of radiation treatment as a tool to check patient 
positioning. Usually the boney anatomy is used to align the patient and does not require nearly as much 
radiation as diagnostic images. The low dose and imaging frequency of CBCT make it an ideal candidate 
to acquire temporal information from despite its poor quality. Fave, Mackin (74) demonstrated that 
even with the large noise and poor image quality of CBCT images, radiomic features can be extracted 
from them as long as certain conditions are met. These conditions include: using consistent imaging 
protocols, relative differences of features, and limiting the patient set to those with less than 1cm of 
tumor motion. The changes in radiomic features after therapy or delta radioimcs will be discussed later 
in this review. 
 For superficial tumors, ultrasound imaging is available and should be considered for radiomic 
analysis for its quick and non-ionizing properties. It has been demonstrated that an ultrasound signature 
like gray-level co-occurrence matrix could differentiate radiation induced damage; and an ultrasound 
method called Nakagami parameters, allows a differentiation between normal and post radiation 
induced parotid glands and neck fibrosis (24, 25, 75). In addition, sonoelastography, the interrogation of 
elastic properties of tissue using ultrasound, has been explored as a tool for breast cancer and thyroid 
malignancy identification (76-78). The radiomics approach was applied to both strain and shear-wave 
elastography in Zhang et. al. 2017 (78) and Zhang et. al. 2015 (76) respectively and the 2017 paper 
coined the term sonoelastomics. Both papers demonstrated that radiomic features derived from 
sonoelastographic images can achieve high AUC, accuracy, sensitivity, and specificity in differentiating 
breast tumors. The authors go on to suggest that like the recent trend of radiomics, radiomic features in 
elastography should be applied to predicting normal tissue toxicity and early treatment response. 
 
4. Potential applications of Radiomics in Radiation Therapy 
The use of radiomics to objectively and quantitatively describe tumors in medical imaging has many 
potential uses in advancing cancer radiation therapy. It’s been demonstrated in this review that 
radiomic features are valuable and objective sources of information that allow for accurate diagnosis 
and prediction of patient outcomes. To help further develop the field of radiomics and integrate it to 
standard of care, many groups have been streamlining the process with automatic segmentation, 
machine learning, and other novel methods. Simultaneously, other groups have been applying the 
radiomic process in different modalities and methods such as sonoelastomics, radiomic features 
extracted from ultrasounds, and delta radiomics, observing the change in radioimc features over time. In 
short, radiomics would positively impact radiation therapy in three main areas: 1) Reducing disease 
segmentation time; 2) Reducing disease classification time and providing additional information about 
the disease classification; and 3) Predicting patient survival curves and normal tissue toxicity. 
 Automatic segmentation would be useful in clinical oncology in two ways: 1) it would be an 
objective, reproducible, and standardizable method of finding a region of interest than the subjective 
human segmentation methods and 2) it would significantly reduce physician disease segmentation time. 
In CT alone there have been results suggesting that automatic or semi-automatic segmentation methods 
are as accurate and more stable than manual contouring that yields more reproducible imaging 
descriptors throughout multiple sites (79-81). Methods like fuzzy locally adaptive Bayesian (FLAB) 
segmentation are promising automatic segmentation methods (82) that may help in developing 
computer aided detection (CAD) systems. CAD systems have been successfully tested on lung nodules 
(83) and are expected to be able to identify many other sites. These radiomic feature based systems 
complement the qualitative and semi-quantitative radiologists’ annotations demonstrating a symbiotic 
relationship between semantic features and textural features (84). The CAD approach can be applied 
infields: better assessing cancer risk through more accurate identification of the site and lowering false-
positive detection rates (85). One present CAD method involves using texture analysis to analyze the 
distribution and heterogeneity of SUV and CT values for malignant and benign bone and soft-tissue 
lesions for improved differential diagnosis on (18)F-FDG PET/CT images (86). These automatic 
segmentation methods, when trained properly with applicable features, performed admirably with 
speeds up to 1.54 seconds per slice, about 10-30 seconds per patient, in brain gliomas; significantly 
faster than manual segmentation methods (87). 
 These automatic methods require complex algorithms to solve difficult problems and machine 
learning approaches are becoming more involved as computational power becomes increasingly more 
powerful and affordable. An example of an ambitious, fully automatic project evaluates the potential of 
Rad-TRaP framework that comprises three distinct modules: 1: a module for radiomics based detection 
of PCa lesions on mpMRI via a feature enabled machine learning classifier, 2: a multi-modal deformable 
co-registration scheme to map tissue, organ, and delineated target volumes from MRI onto CT, 3: 
generation of a radiomics based dose plan on MRI for brachytherapy and on CT for EBRT using the target 
delineations transferred from the MRI to the CT (88). This framework could potentially handle a patient 
from diagnosis to treatment planning and would speed up the pre-treatment process significantly. 
However, due to the high learning curve of using machine learning in a clinical setting, there are many 
barriers to the clinicians adopting it quickly. These barriers could be overcome by understanding the 
primary principles of machine learning (ML) in a clinical setting as outlined in Kang et. al. (89). These 
primary principles of ML are: 1) data or feature source, dosimetric and non-dosimetric information; 2) 
supervised or non-supervised feature selection; 3) the ML method used, whether it be random forests, 
linear regressions, or neural networks; 4) cross-validation methods to generalize the model; 5) testing 
the generalized model with external data; and 6) comparing with different established models, 
frameworks to show improvements against the current standard. These principles will allow the 
clinicians to understand ML at a basic level for discussion and introduction into the clinic. While the 
clinician’s knowledge to apply machine learning methods is important, another limiting factor becomes 
the library of useful data for the application. A large and detailed library of clinical and non-clinical data 
would be required for a ML system to work effectively. However, this may not be the case for many 
studies and could be rectified with the use of either rapid or transfer machine learning methods where 
both methods use a smaller datasets as a seed to extrapolate and solve the identification, classification, 
and prediction problems (90) (91). 
 Some novel methods of extracting radiomic information that could be processed through 
machine learning include using the surrounding tissue to identify tumors like the heterogeneity of 
background parenchymal enhancement to identify triple-negative breast cancers (92) or the peri-
tumoral fat to correlate pathologically involved axillary nodes (93). Other methods include using 
radiographic atlases of specific cancer phenotypes to provide insight into niche locations for cancer cells 
of origin (94). Another possible method is extracting features from novel imaging modalities and 
radiotracers. Novel modalities like light microscopy can provide a bridge between imaging features and 
tumor microenvironment (95). Others include the use of novel tracers like 3, 4-dihydroxy-6-(18)F-fluoro-
l-phenylalanine ((18)F-FDOPA) to extract features that rely on unique tracer pathways. 18F-FDOPA 
image analysis has been shown to predict low grade glioma recurrences and look promising as an 
alternative radiotracer (96, 97). 
 One of the most important issues in cancer therapy is predicting treatment response in terms of 
normal tissue toxicity. It is common to build treatment risk models through clinical data, dosimetric 
evaluation, and semantic image features. Recently, a paper (98) has used clinical, dosimetric, and image 
based features to build a classification model for normal tissue toxicity. This paper approached the 
problem of radiation induced shrinkage of parotid glands and the associated long term xerostomia, 
dryness of the mouth, with machine learning to predict the at-risk patients. This group used a 
Likelihood-Fuzzy Analysis method that allows the management of heterogeneous variables as well as 
missing data on a cohort of head and neck cancer patients that underwent radiotherapy. This method 
allowed the combination of various sources of information: clinical, dosimetric, and radiomic data, to 
create a classification model predicting the risk of parotid gland shrinkage and 12-month xerostomia. It 
concluded that while known predictors of normal tissue toxicity were verified, radiomic feature-based 
models were the best performing. 
 Predictive models are great for pre-treatment risk analysis but once treatment has ended, it is 
difficult to characterize the extent of the radiation induced damage due to the discrepancies in 
physician-based and patient-based assessments. Two papers (25, 99) have suggested two ultrasound 
based methods: gray-level co-occurrence matric (GLCM) features and Nakagami parameters respectively, 
to objectively identify the extent of radiation induced fibrosis. GLCM features were used on the basis 
that normal parotid glands exhibit homogeneous echotexture while radiation induced parotid glands 
exhibit heterogeneous echotexture. Nakagami parameters are images created from specific statistical 
distributions, parameters, of the raw ultrasound signals to highlight the underlying tissue structure. Both 
studies showed significant differences in the ultrasound GLCM features and Nakagami parameters 
between normal and post-therapy parotid glands representing radiation induced fibrosis. 
 Most of the current literature has been about predicting clinical endpoints, usually overall 
survival or normal tissue toxicity, from pre-clinical information. However, recent papers have suggested 
and explored the concept of delta radiomics. Delta radiomics is a concept coined early 2016 observing 
that the change in radiomic features during treatment may have information about early chemotherapy 
treatment response for NSCLC (34, 100). Before it was coined in 2016, other papers have already 
explored the changes in radiomic features before and after treatment for metastatic renal cell cancer, 
colorectal liver metastases, and radiation pneumonitis (101-103). Two of those papers, (101, 102), 
concluded that the changes in two features: entropy and uniformity, representing texture irregularity 
and homogeneity respectively, were better at treatment response evaluation than the Response 
Evaluation Criteria In Solid Tumors (RECIST) standard. The other paper, (103), found 12 textural features 
changed significantly for patients with radiation pneumonitis (RP) grade 2 or above; five of which were 
significant for grade 3 RP or above. The results suggest that delta radiomics could allow for stratification 
models for different grades of RP. 
 The development of delta radiomics in recent years is exemplified by two papers. The first, Aerts, 
Grossmann (34), was a retrospective pilot study to see if radiomic features could identify gefitinib 
responders, patients with EGFR mutations, in NSCLC patients. The study compared features from pre-
treatment and post three-week treatment to see which features or the change in features was the most 
predictive of EGFR mutation. From the 183 features extracted from both images, only pre-treatment 
Laws-Energy 10 and delta volume, maximum diameter, and Gabor Energy features were significantly 
associated with mutation status. Physical tumor features like volume and maximum diameter have been 
historically correlated with overall survival, metastasis status, and now mutation status; they may not be 
an early response feature. However, Laws-Energy 10 and delta Gabor Energy has the potential to add 
predictive value to the current models of treatment response and may be seen earlier than current 
indicators. Expanding on this pilot study (104) used delta radiomic features from weekly 4DCT images to 
interrogate the effectiveness of the delta features. The study concluded that while the selected radiomic 
features changed significantly on a dose or fraction basis, delta radiomic features did not add significant 
value to pre-treatment feature models. Some possible cause for the low impact of delta radiomic 
features are: delta feature selection and model building. The delta features were initially selected from 
those that had some prognostic value in pre-treatment images and the delta radiomics model was built 
by adding to other models. This may have culled features that are not prognostic in one image but are 
prognostic in their changes along treatments and may have reduced the impact of a purely delta 
radiomics prognostic model. There are many implications which will be discussed later.  
 Additionally, a group has shown that radiomic features are promising in differentiating patients 
with and without Meniere's disease (MD), a disorder of the inner ear that can cause vertigo, tinnitus, 
and hearing loss (105) which could mean that radiomic features could be identified for other diseases 
and conditions with previously hidden phenotypic patterns. 
 
5. Challenges of radiomics 
Although there are many applications of radiomics, there are also many challenges to it. Most of these 
challenges are based on the quality of the image data that may be inherent in the modality itself such as 
the poor resolution of PET images or the lack of standardization of imaging techniques, parameters, and 
models that vary from institution to institution. These differences can include: device specifications 
between brands and models, image acquisition parameters such as image resolution, slice thickness, 
timing of contrast agent use, etc.; and volume segmentation methods. The effects of different imaging 
protocols, devices, and parameters are not fully understood and may introduce unknown errors that 
reduce the validity of the correlations derived from radiomic analysis and many studies (106-108) have 
called for more research into feature robustness. While these standardization problems could be 
addressed using robust ML models like neural networks (108) and/or robust features like co-occurance 
matrix and histogram features (106, 107), the authors believe that a communal effort in creating, testing, 
and identifying robust radiomic features across machines, models, protocols, and parameters are 
necessary for the acceleration of radiomic input in the clinical setting. 
 For all modalities, segmentation is essential to the radiomics process as the systems and 
algorithms will only look at the regions of interest outlined. However, inter-observer variability depends 
significantly on the institutions’ protocols, observer preference, and requires a significant time 
commitment for quality segmentation. For example, the common process of using various thresholding 
can affect segmentation especially in those modalities with low resolution and/or high noise (109-111). 
The significant variability insists consistency measures, introducing the need for semi- or automatic 
segmentation processes as mentioned in section 4. When compared to manual segmentation, a semi-
automatic segmentation using 3D slicer, image analysis software with interactive segmentation, 
improved feature quantification reproducibility and robustness (80). Fully automatic segmentation 
methods are available, like one mentioned in Zhang et. al. (112) that used a random forest classifiers to 
segment a background and four tumor regions to extract features from them. 
 In CT, peak tube voltage, tube current, voxel size, image discretization, Hounsfield unit threshold, 
contrast enhancement, slice thickness, and convolution kernel are among the most basic parameters 
that affect radiomic features (113-115). These parameters should be standardized for consistent 
radiomic analysis across institutions and protocols within reason as some parameters such as peak tube 
voltage are more robust to variability than tube current (115). Along with those basic parameters, there 
are a few more parameters that can affect radiomic features such as average intensity projection (AIP), 
free breathing (FB), and end-of-exhale-phase where AIP images contained more DM features than the 
rest (115, 116). While features can vary, many features like filtered entropy and uniformity are robust to 
the variation in breathing phase and averaged sets that suggest their strong representation of the tumor 
(115). Similarly, respiratory gated PET images reduced smearing and improved the quantitation of FDG 
uptake in lesions (42). 
 As mentioned before, because of the poor spatial resolution and high noise in PET (109), 
changes in discretization of image values can greatly affect the textural features (117). This was 
observed in (118) where grid size had a larger impact on features, like cluster shade and zone 
percentage, than image iteration number and FWHM. Smoothing does not affect the measurements 
much (119) but once again, quantization parameters have large effects on the precision of 
heterogeneity measurements (120). Interestingly, there seems to be a lower limit of how small a volume 
can be for accurate feature extraction. Tumor volumes less than 45cm3 significantly affected 
intratumoral uptake heterogeneity comparisons in PET (121).  
 For multi-modalities like PET/CT or MRI/CT for perfusion and diffusion studies can be difficult to 
register due to the distortions of the volume of interest (122). An effective registration algorithm is 
required to minimize registration error (123). A technique using Pearson correlation has shown that 
instead of using mutual information and correlation ratios as metrics for cost function analysis, a 
weighted local Pearson coefficient improved significantly (124). 
Other errors include study design errors in which type-1 errors, false positives, are too prevalent 
for accurate association of textural features derived from images to patient survival (125).  To minimize 
type-1 errors, a few methods are available: Benjamini-Hochberg correction (126), bootstrap method 
correction (127), and if the sample is small enough, an algorithm parameterized by the variance of the 
spreading distribution can find features robust relative to the spread of the sample (128). 
While tumor type, segmentation, modality, and study designs can affect the strength of the 
correlations derived from radiomic analysis and require careful observation, the quality of the extracted 
features should be validated to be robust and consistent across those variables. The robustness and 
consistency of these features can be evaluated by observing the changes due to geometric 
transformations of the regions of interest and variability of intensities (129). Another method of 
producing the most significant features is to reduce the number of redundant features through principal 
components analysis (PCA) along with the Rough set approach to extract the best classification features 
(130). 
Lastly, one of the fundamental principles of the scientific method is reproducibility. However, it 
is difficult to reproduce results when proprietary or in-house software is used to extract feature. The 
differences in the software may be minor and can range from the specific names of features or the 
parameters in which they are pre-processed, and calculated but can have a debilitating effect on the 
verification of published studies. A recent review showed that there are several software available for 
each part of the radiomic workflow such as 3DSlicer, MIM, itk-SNAP, LuTA, and Velocity ROI just for 
image segmentation each with various capabilities and differences (131). 
 
6. Discussion 
Radiomics, at most, has played an observatory role in oncology so far. The majority of the literature is 
based on retrospective data that yield specialized features or signatures for specific cancers. While some 
papers have suggested the translational ability of certain features across cancer types like lung cancer 
and head and neck cancer (19), there hasn’t been a consolidated list of features for cancers as 
recommendations for future studies or indications for eventual use in clinical practice. Much of this can 
be attributed to the lack of standardization in extracting radiomic features. A solution may be using a 
centralized or universally used software platform like the Computational Environment for Radiotherapy 
Research (CERR) that can import, display, analyze, and create filetypes of treatment plans from different 
institutions and protocols for easy sharing of information (132). While CERR is a software platform for 
radiation treatment plans, there have been attempts like the Chang-Gung Image Texture Analysis 
(CGITA) (133) and MaZda (134), developed for PET and MRI respectively, that can specifically import, 
display, analyze, and create radiomic features. Most recently, a more general and flexible radiomics 
software platform, Imaging Biomarker Explorer (IBEX), has been developed at MD Anderson for various 
applications and aptitudes in radiomics (135). 
While the field of radiomics stemmed from the diagnosis of cancers and identification of 
prognostic factors, there should be a shift towards clinical applications. As therapists, radiologists, and 
researchers the ultimate goal is to improve the quality of life and patient treatment through the 
application of research. Much of the published work has laid the groundwork to demonstrate the 
prognostic power of radiomic features as a non-invasive and repeatable interrogation method for 
cancers and is easily integrable to the standard of care. As mentioned in recent papers, Aerts (136) and 
Fave, Zhang (104), the integration of radiomics into clinical practice depends largely on three factors: 
adding to the response prediction of current models, earlier treatment response identification, and 
standardization of radiomics starting from image acquisition to feature extraction. While radiomics is a 
very hot topic, the lack of standardization from imaging acquisition to the naming of features present a 
difficult barrier from it going to the next level. However, groups like the Quantitative Imaging Biomarker 
Alliance from the Radiological Society of North America and Quantitative Imaging Network are working 
to find and standardize optimal imaging parameters and protocols (136). Additionally, software like 
Imaging Biomarker Explorer (IBEX) work to create a centralized but modular radiomic software platform 
to allow consistent data sharing among groups and institutions (135). The ability to share, compare, and 
verifying the features and conclusions of studies are an important but low impact work that needs to be 
done.   
 
7. Conclusion 
 Radiomics promises a quantitative solution to the problem of cancer therapy by improving the 
characterization of tumors through additional datasets and provide further insights into the diagnosis 
and patient care decision making process. Diseases like glioblastomas and prostate cancer that are very 
heterogeneous do not yield as much information as homogeneous cancers in biopsies. A non-invasive 
and repeatable method of interrogating the tumor volume, like medical imaging, for phenotypic 
information is invaluable for pre-therapy risk analysis. In addition, an advantage of radiomics is that it 
will not add more radiation burden to patients as it is a field that post-processes images that are part of 
routine standard of care.  
Advances in gene sequencing, phenotypic correlation to clinical outcomes, and machine learning 
promises a future in which personalized medicine with high sensitivity and specificity. Addressing the 
limitations of radiomics is the next step in which an emphasis on gathering quality data, extracting the 
most adequate features, and thorough validation is the hallmark of a good radiomic study. The 
assessment of radiomic data and models must be driven to be clinically validated, applicable, and 
universal outside of academic study. This has already been started by the recent TRIPOD (Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statements in which 
the clinical usefulness and application of prognostic or diagnostic models of an author’s study are 
reported through a transparent checklist of a study (137). Ultimately, the goal of radiomics is to improve 
the standard of care by providing more information to healthcare providers in an easily understandable, 
efficient, and clinically relevant manner. 
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